New Insights to Cancer Therapy Resistance

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1842

Special Issue Editor


E-Mail Website
Guest Editor
West German Cancer Center, Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany
Interests: DNA repair; immune response; cancer therapy; software tools; molecular biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent decades, considerable advances have been made in understanding tumor-driving mechanisms, which have fueled the development of novel therapeutic approaches benefitting many patients. The major progress is represented by the further development of immunotherapy and targeted therapy with small molecules, e.g., KRASG12C-specific inhibitors. Despite this considerable progress, cancer is an evolving disease, and resistance develops almost immediately and is found in clinics.

The current Special Issue addresses the emerging questions of how these forms of resistance occur and reveal the underlying mechanisms. The collation of more detailed knowledge obtained from experts of different cancer research fields addressing the relationships of molecular mechanisms and resistances occurring in clinics offers a great opportunity to promote an improved understanding and the development of resistance-overcoming approaches.

Dr. Sebastian Oeck
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapy
  • resistance
  • molecular mechanisms
  • clinical approaches
  • novel therapeutic approaches

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 1108 KiB  
Review
The Multifaceted Roles of Lamins in Lung Cancer and DNA Damage Response
by Janina Janetzko, Sebastian Oeck and Alexander Schramm
Cancers 2023, 15(23), 5501; https://doi.org/10.3390/cancers15235501 - 21 Nov 2023
Viewed by 1205
Abstract
Emerging evidence suggests that lamin functions are not limited to maintaining the structural integrity of the nucleus in eukaryotic cells but that these functions affect many facets of cancer biology. An increasing number of reports suggest that adaptive changes in the lamin subtype [...] Read more.
Emerging evidence suggests that lamin functions are not limited to maintaining the structural integrity of the nucleus in eukaryotic cells but that these functions affect many facets of cancer biology. An increasing number of reports suggest that adaptive changes in the lamin subtype composition within the nuclear lamina could affect essential features of cancer development and aggressiveness. These include regulation of cellular stiffness and mobility as well as epithelial-to-mesenchymal transition (EMT), all of which directly impact the metastatic properties of cancer cells. Additionally, insights from studies on the physiological functions of lamins suggest that cancer cells could hijack the ability of lamins to modify chromatin accessibility, cell cycle regulation, and DNA damage response. Here, we present a comprehensive overview of the role of lamins in lung cancer and DNA damage response, which is commonly evoked by lung cancer therapies. Collectively, this information should help better understand the sometimes-conflicting reports on lamin functions in lung cancer as well as in other cancer types. Full article
(This article belongs to the Special Issue New Insights to Cancer Therapy Resistance)
Show Figures

Figure 1

Back to TopTop